Raymond Stallings


Raymond Stallings

Director of Research and Innovation & Professor of Cancer Genetics, Royal College of Surgeons in Ireland

Professor Ray Stallings became Director of Research in 2012, after having joined RCSI as the Chair of Cancer Genetics in 2007. Professor Stallings has held faculty and scientific leadership positions at a number of major research centres, hospitals and universities in Ireland and the United States, including the University of Texas Health Science Centre at San Antonio, University College Dublin, Our Lady’s Children’s Hospital, Dublin, the University of Pittsburgh, the University of California, and the University of Texas M.D. Anderson Cancer Centre in Houston. An author and co-author of over 180 journal articles, books, and book chapters, Prof. Stallings is an internationally recognised leader in the area of cancer genomics and is the recipient of many major peer-reviewed grant awards from national and international sources. Ray’s current research is focused on the development of novel therapeutic approaches for the treatment of the childhood cancer neuroblastoma.

 

Raymond Stallings

Director of Research and Innovation & Professor of Cancer Genetics, Royal College of Surgeons in Ireland

Olga Piskareva
Position: Researcher and Honorary Lecturer at RCSI
olgapiskareva@rcsi.ie

Role:
Olga coordinates the research for the Cancer Genetics Laboratory

Modulation of drug resistance in high-risk neuroblastoma through exosomal miRNA

Summary: Neuroblastoma is a childhood cancer caused by the abnormal growth and development of neural crest cells. The disease commonly affects children age 5 years or younger. Approximately 50% of children have cancer cells that have migrated to distant sites in the body and formed tumour masses at the time of diagnosis. The main challenge in treating neuroblastoma is to combat tumour metastasis and development of resistance to multiple chemotherapeutic drugs. Despite major advances in available therapies, children with drug resistant and/or recurrent neuroblastoma have a dismal outlook with 5-year survival rates of less than 20%. This project aims to develop biomarkers of tumour response to drugs that might be used to help select patients for treatment, and identify novel targets for the development of more effective personalised therapy with anticipated improvement in clinical outcome. This work will contribute to more efficient design of re-initiation treatment, sparing patients unnecessary rounds of chemotherapy and ultimately increasing survival. The most important achievement of the research project will be contribution to a panel of circulating biomarkers that will be prospectively analysed in the next SIOPEN high-risk trial. These new circulating markers will benefit children with high-risk neuroblastoma whose tumours have relapsed, leading to less harmful and more tailored treatment options.

The list of publications below is automatically derived from MEDLINE/PubMed. As a result, there may be incorrect or missing publications.

Soriano A, Masanas M, Boloix A, Masiá N, París-Coderch L, Piskareva O, Jiménez C, Henrich KO, Roma J, Westermann F, Stallings RL, Sábado C, de Toledo JS, Santamaria A, Gallego S, Segura MF, 2019 Jun, Functional high-throughput screening reveals miR-323a-5p and miR-342-5p as new tumor-suppressive microRNA for neuroblastoma. Cell Mol Life Sci, DOI: 10.1007/s00018-019-03041-4
Curtin C, Nolan JC, Conlon R, Deneweth L, Gallagher C, Tan YJ, Cavanagh BL, Asraf AZ, Harvey H, Miller-Delaney S, Shohet J, Bray I, O'Brien FJ, Stallings RL, Piskareva O, 2018 Apr 1, A physiologically relevant 3D collagen-based scaffold-neuroblastoma cell system exhibits chemosensitivity similar to orthotopic xenograft models. Acta Biomater, DOI: 10.1016/j.actbio.2018.02.004
Smith S, Fernando T, Wu PW, Seo J, Ní Gabhann J, Piskareva O, McCarthy E, Howard D, O'Connell P, Conway R, Gallagher P, Molloy E, Stallings RL, Kearns G, Forbess L, Ishimori M, Venuturupalli S, Wallace D, Weisman M, Jefferies CA, 2017 May, MicroRNA-302d targets IRF9 to regulate the IFN-induced gene expression in SLE. J Autoimmun, DOI: 10.1016/j.jaut.2017.03.003
Spain E, Adamson K, Elshahawy M, Bray I, Keyes TE, Stallings RL, Forster RJ, 2017 Feb 27, Hemispherical platinum : silver core : shell nanoparticles for miRNA detection. Analyst, DOI: 10.1039/c6an02609e
Nolan J, Stallings RL, Piskareva O, 2017, Assessment of Basic Biological Functions Exerted by miRNAs. Methods Mol Biol, DOI: 10.1007/978-1-4939-6524-3_2
Soriano A, París-Coderch L, Jubierre L, Martínez A, Zhou X, Piskareva O, Bray I, Vidal I, Almazán-Moga A, Molist C, Roma J, Bayascas JR, Casanovas O, Stallings RL, Sánchez de Toledo J, Gallego S, Segura MF, 2016 Feb 23, MicroRNA-497 impairs the growth of chemoresistant neuroblastoma cells by targeting cell cycle, survival and vascular permeability genes. Oncotarget, DOI: 10.18632/oncotarget.7005
Nolan K, Walter F, Tuffy LP, Poeschel S, Gallagher R, Haunsberger S, Bray I, Stallings RL, Concannon CG, Prehn JH, 2016 Mar, Endoplasmic reticulum stress-mediated upregulation of miR-29a enhances sensitivity to neuronal apoptosis. Eur J Neurosci, DOI: 10.1111/ejn.13160
Decock A, Ongenaert M, Cannoodt R, Verniers K, De Wilde B, Laureys G, Van Roy N, Berbegall AP, Bienertova-Vasku J, Bown N, Clément N, Combaret V, Haber M, Hoyoux C, Murray J, Noguera R, Pierron G, Schleiermacher G, Schulte JH, Stallings RL, Tweddle DA, Children’s Cancer and Leukaemia Group (CCLG)., De Preter K, Speleman F, Vandesompele J, 2016 Jan 12, Methyl-CpG-binding domain sequencing reveals a prognostic methylation signature in neuroblastoma. Oncotarget, DOI: 10.18632/oncotarget.6477
Keating SE, Ní Chorcora C, Dring MM, Stallings RL, O'Meara A, Gardiner CM, 2015 Sep, Increased frequencies of the killer immunoglobulin-like receptor genes KIR2DL2 and KIR2DS2 are associated with neuroblastoma. Tissue Antigens, DOI: 10.1111/tan.12608
Piskareva O, Harvey H, Nolan J, Conlon R, Alcock L, Buckley P, Dowling P, Henry M, O'Sullivan F, Bray I, Stallings RL, 2015 Aug 10, The development of cisplatin resistance in neuroblastoma is accompanied by epithelial to mesenchymal transition in vitro. Cancer Lett, DOI: 10.1016/j.canlet.2015.05.004
Miller-Delaney SF, Bryan K, Das S, McKiernan RC, Bray IM, Reynolds JP, Gwinn R, Stallings RL, Henshall DC, 2015 Mar, Differential DNA methylation profiles of coding and non-coding genes define hippocampal sclerosis in human temporal lobe epilepsy. Brain, DOI: 10.1093/brain/awu373
Rihani A, De Wilde B, Zeka F, Laureys G, Francotte N, Tonini GP, Coco S, Versteeg R, Noguera R, Schulte JH, Eggert A, Stallings RL, Speleman F, Vandesompele J, Van Maerken T, 2014, CASP8 SNP D302H (rs1045485) is associated with worse survival in MYCN-amplified neuroblastoma patients. PLoS One, DOI: 10.1371/journal.pone.0114696
Lee S, Rahnenführer J, Lang M, De Preter K, Mestdagh P, Koster J, Versteeg R, Stallings RL, Varesio L, Asgharzadeh S, Schulte JH, Fielitz K, Schwermer M, Morik K, Schramm A, 2014, Robust selection of cancer survival signatures from high-throughput genomic data using two-fold subsampling. PLoS One, DOI: 10.1371/journal.pone.0108818
Planells-Ferrer L, Urresti J, Soriano A, Reix S, Murphy DM, Ferreres JC, Borràs F, Gallego S, Stallings RL, Moubarak RS, Segura MF, Comella JX, 2014 Sep 4, MYCN repression of Lifeguard/FAIM2 enhances neuroblastoma aggressiveness. Cell Death Dis, DOI: 10.1038/cddis.2014.356
Harvey H, Piskareva O, Creevey L, Alcock LC, Buckley PG, O'Sullivan MJ, Segura MF, Gallego S, Stallings RL, Bray IM, 2015 Apr 1, Modulation of chemotherapeutic drug resistance in neuroblastoma SK-N-AS cells by the neural apoptosis inhibitory protein and miR-520f. Int J Cancer, DOI: 10.1002/ijc.29144
Rihani A, Van Maerken T, De Wilde B, Zeka F, Laureys G, Norga K, Tonini GP, Coco S, Versteeg R, Noguera R, Schulte JH, Eggert A, Stallings RL, Speleman F, Vandesompele J, 2014 Oct, Lack of association between MDM2 promoter SNP309 and clinical outcome in patients with neuroblastoma. Pediatr Blood Cancer, DOI: 10.1002/pbc.24927
Bryan K, Terrile M, Bray IM, Domingo-Fernandéz R, Watters KM, Koster J, Versteeg R, Stallings RL, 2014 Feb, Discovery and visualization of miRNA-mRNA functional modules within integrated data using bicluster analysis. Nucleic Acids Res, DOI: 10.1093/nar/gkt1318
Lynch J, Meehan MH, Crean J, Copeland J, Stallings RL, Bray IM, 2013, Metastasis suppressor microRNA-335 targets the formin family of actin nucleators. PLoS One, DOI: 10.1371/journal.pone.0078428
Miller-Delaney SF, Das S, Stallings RL, Henshall DC, 2013, Investigating gene promoter methylation in a mouse model of status epilepticus. Methods Mol Biol, DOI: 10.1007/978-1-62703-607-8_7
McCoy RJ, Widaa A, Watters KM, Wuerstle M, Stallings RL, Duffy GP, O'Brien FJ, 2013 Nov, Orchestrating osteogenic differentiation of mesenchymal stem cells--identification of placental growth factor as a mechanosensitive gene with a pro-osteogenic role. Stem Cells, DOI: 10.1002/stem.1482
Wilzén A, Krona C, Sveinbjörnsson B, Kristiansson E, Dalevi D, Øra I, De Preter K, Stallings RL, Maris J, Versteeg R, Nilsson S, Kogner P, Abel F, 2013 Jul 8, ERBB3 is a marker of a ganglioneuroblastoma/ganglioneuroma-like expression profile in neuroblastic tumours. Mol Cancer, DOI: 10.1186/1476-4598-12-70
Bonner C, Nyhan KC, Bacon S, Kyithar MP, Schmid J, Concannon CG, Bray IM, Stallings RL, Prehn JH, Byrne MM, 2013 Aug, Identification of circulating microRNAs in HNF1A-MODY carriers. Diabetologia, DOI: 10.1007/s00125-013-2939-4
Watters KM, Bryan K, Foley NH, Meehan M, Stallings RL, 2013 Apr 8, Expressional alterations in functional ultra-conserved non-coding RNAs in response to all-trans retinoic acid--induced differentiation in neuroblastoma cells. BMC Cancer, DOI: 10.1186/1471-2407-13-184
Creevey L, Ryan J, Harvey H, Bray IM, Meehan M, Khan AR, Stallings RL, 2013 Mar 26, MicroRNA-497 increases apoptosis in MYCN amplified neuroblastoma cells by targeting the key cell cycle regulator WEE1. Mol Cancer, DOI: 10.1186/1476-4598-12-23
Rea G, Stallings RL, Mullarkey M, McKinstry CS, McManus D, Morrison PJ, 2013 Apr, Subcortical white matter abnormalities because of previously undescribed de-novo 14q12-q13.1 triplication. Clin Dysmorphol, DOI: 10.1097/MCD.0b013e32835f7465
Althoff K, Beckers A, Odersky A, Mestdagh P, Köster J, Bray IM, Bryan K, Vandesompele J, Speleman F, Stallings RL, Schramm A, Eggert A, Sprüssel A, Schulte JH, 2013 Sep 1, MiR-137 functions as a tumor suppressor in neuroblastoma by downregulating KDM1A. Int J Cancer, DOI: 10.1002/ijc.28091
Sridhar S, Al-Moallem B, Kamal H, Terrile M, Stallings RL, 2013 Apr, New insights into the genetics of neuroblastoma. Mol Diagn Ther, DOI: 10.1007/s40291-013-0019-6
Domingo-Fernandez R, Watters K, Piskareva O, Stallings RL, Bray I, 2013 Feb, The role of genetic and epigenetic alterations in neuroblastoma disease pathogenesis. Pediatr Surg Int, DOI: 10.1007/s00383-012-3239-7
Molenaar JJ, Domingo-Fernández R, Ebus ME, Lindner S, Koster J, Drabek K, Mestdagh P, van Sluis P, Valentijn LJ, van Nes J, Broekmans M, Haneveld F, Volckmann R, Bray I, Heukamp L, Sprüssel A, Thor T, Kieckbusch K, Klein-Hitpass L, Fischer M, Vandesompele J, Schramm A, van Noesel MM, Varesio L, Speleman F, Eggert A, Stallings RL, Caron HN, Versteeg R, Schulte JH, 2012 Nov, LIN28B induces neuroblastoma and enhances MYCN levels via let-7 suppression. Nat Genet, DOI: 10.1038/ng.2436
Decock A, Ongenaert M, Hoebeeck J, De Preter K, Van Peer G, Van Criekinge W, Ladenstein R, Schulte JH, Noguera R, Stallings RL, Van Damme A, Laureys G, Vermeulen J, Van Maerken T, Speleman F, Vandesompele J, 2012 Oct 3, Genome-wide promoter methylation analysis in neuroblastoma identifies prognostic methylation biomarkers. Genome Biol, DOI: 10.1186/gb-2012-13-10-r95
Ryan J, Tivnan A, Fay J, Bryan K, Meehan M, Creevey L, Lynch J, Bray IM, O'Meara A, Tracey L, Davidoff AM, Stallings RL, 2012 Sep 4, MicroRNA-204 increases sensitivity of neuroblastoma cells to cisplatin and is associated with a favourable clinical outcome. Br J Cancer, DOI: 10.1038/bjc.2012.356
Das S, Bryan K, Buckley PG, Piskareva O, Bray IM, Foley N, Ryan J, Lynch J, Creevey L, Fay J, Prenter S, Koster J, van Sluis P, Versteeg R, Eggert A, Schulte JH, Schramm A, Mestdagh P, Vandesompele J, Speleman F, Stallings RL, 2013 Jun 13, Modulation of neuroblastoma disease pathogenesis by an extensive network of epigenetically regulated microRNAs. Oncogene, DOI: 10.1038/onc.2012.311
McKiernan RC, Jimenez-Mateos EM, Sano T, Bray I, Stallings RL, Simon RP, Henshall DC, 2012 Oct, Expression profiling the microRNA response to epileptic preconditioning identifies miR-184 as a modulator of seizure-induced neuronal death. Exp Neurol, DOI: 10.1016/j.expneurol.2012.06.029
Howley R, Kinsella P, Buckley PG, Alcock L, Jansen M, Heffernan J, Stallings RL, Brett FM, Amberger-Murphy V, Farrell MA, 2012 Oct 15, Comparative genomic and proteomic analysis of high grade glioma primary cultures and matched tumor in situ. Exp Cell Res, DOI: 10.1016/j.yexcr.2012.06.007
Jimenez-Mateos EM, Engel T, Merino-Serrais P, McKiernan RC, Tanaka K, Mouri G, Sano T, O'Tuathaigh C, Waddington JL, Prenter S, Delanty N, Farrell MA, O'Brien DF, Conroy RM, Stallings RL, DeFelipe J, Henshall DC, 2012 Jul, Silencing microRNA-134 produces neuroprotective and prolonged seizure-suppressive effects. Nat Med, DOI: 10.1038/nm.2834
Tivnan A, Orr WS, Gubala V, Nooney R, Williams DE, McDonagh C, Prenter S, Harvey H, Domingo-Fernández R, Bray IM, Piskareva O, Ng CY, Lode HN, Davidoff AM, Stallings RL, 2012, Inhibition of neuroblastoma tumor growth by targeted delivery of microRNA-34a using anti-disialoganglioside GD2 coated nanoparticles. PLoS One, DOI: 10.1371/journal.pone.0038129
McKiernan RC, Jimenez-Mateos EM, Bray I, Engel T, Brennan GP, Sano T, Michalak Z, Moran C, Delanty N, Farrell M, O'Brien D, Meller R, Simon RP, Stallings RL, Henshall DC, 2012, Reduced mature microRNA levels in association with dicer loss in human temporal lobe epilepsy with hippocampal sclerosis. PLoS One, DOI: 10.1371/journal.pone.0035921
Lynch J, Fay J, Meehan M, Bryan K, Watters KM, Murphy DM, Stallings RL, 2012 May, MiRNA-335 suppresses neuroblastoma cell invasiveness by direct targeting of multiple genes from the non-canonical TGF-β signalling pathway. Carcinogenesis, DOI: 10.1093/carcin/bgs114
Meehan M, Parthasarathi L, Moran N, Jefferies CA, Foley N, Lazzari E, Murphy D, Ryan J, Ortiz B, Fabius AW, Chan TA, Stallings RL, 2012 Feb 5, Protein tyrosine phosphatase receptor delta acts as a neuroblastoma tumor suppressor by destabilizing the aurora kinase A oncogene. Mol Cancer, DOI: 10.1186/1476-4598-11-6
Miller-Delaney SF, Das S, Sano T, Jimenez-Mateos EM, Bryan K, Buckley PG, Stallings RL, Henshall DC, 2012 Feb 1, Differential DNA methylation patterns define status epilepticus and epileptic tolerance. J Neurosci, DOI: 10.1523/JNEUROSCI.5180-11.2012
Terrile M, Bryan K, Vaughan L, Hallsworth A, Webber H, Chesler L, Stallings RL, 2011, miRNA expression profiling of the murine TH-MYCN neuroblastoma model reveals similarities with human tumors and identifies novel candidate miRNAs. PLoS One, DOI: 10.1371/journal.pone.0028356
De Preter K, Mestdagh P, Vermeulen J, Zeka F, Naranjo A, Bray I, Castel V, Chen C, Drozynska E, Eggert A, Hogarty MD, Izycka-Swieszewska E, London WB, Noguera R, Piqueras M, Bryan K, Schowe B, van Sluis P, Molenaar JJ, Schramm A, Schulte JH, Stallings RL, Versteeg R, Laureys G, Van Roy N, Speleman F, Vandesompele J, 2011 Dec 15, miRNA expression profiling enables risk stratification in archived and fresh neuroblastoma tumor samples. Clin Cancer Res, DOI: 10.1158/1078-0432.CCR-11-0610
Jimenez-Mateos EM, Bray I, Sanz-Rodriguez A, Engel T, McKiernan RC, Mouri G, Tanaka K, Sano T, Saugstad JA, Simon RP, Stallings RL, Henshall DC, 2011 Nov, miRNA Expression profile after status epilepticus and hippocampal neuroprotection by targeting miR-132. Am J Pathol, DOI: 10.1016/j.ajpath.2011.07.036
Santo EE, Ebus ME, Koster J, Schulte JH, Lakeman A, van Sluis P, Vermeulen J, Gisselsson D, Øra I, Lindner S, Buckley PG, Stallings RL, Vandesompele J, Eggert A, Caron HN, Versteeg R, Molenaar JJ, 2012 Mar 22, Oncogenic activation of FOXR1 by 11q23 intrachromosomal deletion-fusions in neuroblastoma. Oncogene, DOI: 10.1038/onc.2011.344
Stallings RL, Foley NH, Bray IM, Das S, Buckley PG, 2011 Oct, MicroRNA and DNA methylation alterations mediating retinoic acid induced neuroblastoma cell differentiation. Semin Cancer Biol, DOI: 10.1016/j.semcancer.2011.07.001
Murphy DM, Buckley PG, Das S, Watters KM, Bryan K, Stallings RL, 2011, Co-localization of the oncogenic transcription factor MYCN and the DNA methyl binding protein MeCP2 at genomic sites in neuroblastoma. PLoS One, DOI: 10.1371/journal.pone.0021436
Murphy DM, Buckley PG, Bryan K, Watters KM, Koster J, van Sluis P, Molenaar J, Versteeg R, Stallings RL, 2011 Jun, Dissection of the oncogenic MYCN transcriptional network reveals a large set of clinically relevant cell cycle genes as drivers of neuroblastoma tumorigenesis. Mol Carcinog, DOI: 10.1002/mc.20722
Bray I, Tivnan A, Bryan K, Foley NH, Watters KM, Tracey L, Davidoff AM, Stallings RL, 2011 Apr 1, MicroRNA-542-5p as a novel tumor suppressor in neuroblastoma. Cancer Lett, DOI: 10.1016/j.canlet.2011.01.016
Buckley PG, Alcock L, Heffernan J, Woods J, Brett F, Stallings RL, Farrell MA, 2011 Mar, Loss of chromosome 1p/19q in oligodendroglial tumors: refinement of chromosomal critical regions and evaluation of internexin immunostaining as a surrogate marker. J Neuropathol Exp Neurol, DOI: 10.1097/NEN.0b013e31820c765b
Tivnan A, Tracey L, Buckley PG, Alcock LC, Davidoff AM, Stallings RL, 2011 Jan 25, MicroRNA-34a is a potent tumor suppressor molecule in vivo in neuroblastoma. BMC Cancer, DOI: 10.1186/1471-2407-11-33
Foley NH, Bray I, Watters KM, Das S, Bryan K, Bernas T, Prehn JH, Stallings RL, 2011 Jul, MicroRNAs 10a and 10b are potent inducers of neuroblastoma cell differentiation through targeting of nuclear receptor corepressor 2. Cell Death Differ, DOI: 10.1038/cdd.2010.172
Tivnan A, Foley NH, Tracey L, Davidoff AM, Stallings RL, 2010 Nov, MicroRNA-184-mediated inhibition of tumour growth in an orthotopic murine model of neuroblastoma. Anticancer Res, DOI: 10.1038/cdd.2010.172
Das S, Foley N, Bryan K, Watters KM, Bray I, Murphy DM, Buckley PG, Stallings RL, 2010 Oct 15, MicroRNA mediates DNA demethylation events triggered by retinoic acid during neuroblastoma cell differentiation. Cancer Res, DOI: 10.1158/0008-5472.CAN-10-1534
Buckley PG, Das S, Bryan K, Watters KM, Alcock L, Koster J, Versteeg R, Stallings RL, 2011 May 15, Genome-wide DNA methylation analysis of neuroblastic tumors reveals clinically relevant epigenetic events and large-scale epigenomic alterations localized to telomeric regions. Int J Cancer, DOI: 10.1002/ijc.25584
Stallings RL, Foley NH, Bryan K, Buckley PG, Bray I, 2010 Sep, Therapeutic targeting of miRNAs in neuroblastoma. Expert Opin Ther Targets, DOI: 10.1517/14728222.2010.510136
Foley NH, Bray IM, Tivnan A, Bryan K, Murphy DM, Buckley PG, Ryan J, O'Meara A, O'Sullivan M, Stallings RL, 2010 Apr 21, MicroRNA-184 inhibits neuroblastoma cell survival through targeting the serine/threonine kinase AKT2. Mol Cancer, DOI: 10.1186/1476-4598-9-83
Buckley PG, Alcock L, Bryan K, Bray I, Schulte JH, Schramm A, Eggert A, Mestdagh P, De Preter K, Vandesompele J, Speleman F, Stallings RL, 2010 Jun 1, Chromosomal and microRNA expression patterns reveal biologically distinct subgroups of 11q- neuroblastoma. Clin Cancer Res, DOI: 10.1158/1078-0432.CCR-09-3215
Heinzen EL, Radtke RA, Urban TJ, Cavalleri GL, Depondt C, Need AC, Walley NM, Nicoletti P, Ge D, Catarino CB, Duncan JS, Kasperaviciūte D, Tate SK, Caboclo LO, Sander JW, Clayton L, Linney KN, Shianna KV, Gumbs CE, Smith J, Cronin KD, Maia JM, Doherty CP, Pandolfo M, Leppert D, Middleton LT, Gibson RA, Johnson MR, Matthews PM, Hosford D, Kälviäinen R, Eriksson K, Kantanen AM, Dorn T, Hansen J, Krämer G, Steinhoff BJ, Wieser HG, Zumsteg D, Ortega M, Wood NW, Huxley-Jones J, Mikati M, Gallentine WB, Husain AM, Buckley PG, Stallings RL, Podgoreanu MV, Delanty N, Sisodiya SM, Goldstein DB, 2010 May 14, Rare deletions at 16p13.11 predispose to a diverse spectrum of sporadic epilepsy syndromes. Am J Hum Genet, DOI: 10.1016/j.ajhg.2010.03.018
Tivnan A, Stallings RL, 2010 May, Neuroblastoma-specific expression of potential therapeutics cannot be achieved using a promoter region of the NCX (TLX2) gene. Cancer Gene Ther, DOI: 10.1038/cgt.2009.90

Please visit PubMed for more information on Raymond Stallings's publications